Lupin moves up on signing license and supply agreement with Sino Universal Pharmaceuticals
Lupin is currently trading at Rs. 2009.00, up by 8.65 points or 0.43% from its previous closing of Rs. 2000.35 on the BSE.
The scrip opened at Rs. 1981.40 and has touched a high and low of Rs. 2011.90 and Rs. 1981.40 respectively. So far 5566 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2403.45 on 02-Jan-2025 and a 52 week low of Rs. 1531.15 on 21-Jun-2024.
Last one week high and low of the scrip stood at Rs. 2049.80 and Rs. 1981.40 respectively. The current market cap of the company is Rs. 91405.31 crore.
The promoters holding in the company stood at 46.92%, while Institutions and Non-Institutions held 46.88% and 6.20% respectively.
Lupin has signed a license and supply agreement with Sino Universal Pharmaceuticals (SUP), for the commercialization of Tiotropium Dry Powder Inhaler (DPI), 18 mcg/capsule, in the Chinese market, for the treatment of chronic obstructive pulmonary disease (COPD).
As per the agreement, SUP will obtain regulatory approvals for selling Tiotropium DPI in China, while Lupin will be the marketing authorization holder and responsible for manufacturing of the product.
Tiotropium DPI is known for its efficacy in improving lung function and quality of life for patients suffering from respiratory conditions. This partnership will enable Lupin to expand its footprint in China, ensuring that patients have timely access to innovative and high-quality healthcare solutions, considering the increasing prevalence of respiratory conditions.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
